Table 1.
Profile of metronidazole-related resistance genotypes in biopsies.
| END | FS | 16re | 21re | 53re | 62re | 68re | 91re | 108re | 118re | WT | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| S (25) | 3 (12.0%) | 3 (12.0%) | 3 (12.0%) | 3 (12.0%) | 2 (8.0%) | 6 (24.0%) | 4 (16.0%) | 0 (0.0%) | 1 (4.0%) | 3 (12.0%) | 3 (12.0%) |
| R (99) | 12 (12.1%) | 22 (22.2%) | 11 (11.1%) | 13 (13.1%) | 10 (10.1%) | 17 (17.2%) | 12 (12.1%) | 7 (7.1%) | 7 (7.1%) | 5 (5.1%) | 14 (14.1%) |
| Tot (124) | 15 (12.1%) | 25 (20.2%) | 14 (11.3%) | 16 (12.9%) | 12 (9.7%) | 23 (18.5%) | 16 (12.9%) | 7 (5.6%) | 8 (6.5%) | 8 (6.5%) | 17 (13.7%) |
16re, the 16th amino acid was replaced by another amino acid.
END, stop codon mutations, FS, frameshift; R, resistant; S, susceptible; Tot, total; WT, wild type.